Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction

Clinical Science

Volumn 112, Issue 1-2, 2007, Pages 43-49

  Yasuda, Satoshi ^a,b   Miyazaki, Shunichi ^a   Kinoshita, Hideyuki ^a   Nagaya, Noritoshi ^a   Kanda, Munetake ^a   Goto, Yoichi ^a   Nonogi, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Angina pectoris; Brain natriuretic peptide (BNP); Metalloproteinase (MMP); Remodelling; Statin; Tissue inhibitor of metalloproteinases (TIMP)

Indexed keywords

ANGIOTENSIN RECEPTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; GELATINASE A; GELATINASE B; HEPARIN; PLASMINOGEN ACTIVATOR; PRAVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR ALPHA;

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; ANGINA PECTORIS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL; ENZYME ACTIVATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PRAVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33846288014     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060110     Document Type: Article

References (30)

1. Sutton, M. G. and Sharpe, N. (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981-2988
2. Yousef, Z. R., Redwood, S. R. and Marber, M. S. (2000) Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 83, 76-80
3. White, H. D., Norris, R. M., Brown, M. A., Brandt, P. W., Whitlock, R. M. and Wild, C. J. (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76, 44-51
4. Weisman, H. F. and Healy, B. (1987) Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog. Cardiovasc. Dis. 30, 73-110
5. Creemers, E. E., Cleutjens, J. P., Smits, J. F. and Daemen, M. J. (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89, 201-210
6. Spinale, F. G. (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90, 520-530
7. Cleutjens, J. P., Kandala, J. C., Guarda, E., Guntaka, R. V. and Weber, K. T. (1995) Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol. 27, 1281-1292
8. Rohde, L. E., Ducharme, A., Arroyo, L. H. et al. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99, 3063-3070
9. Heymans, S., Luttun, A., Nuyens, D. et al. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5, 1135-1142
10. Ducharme, A., Frantz, S., Aikawa, M. et al. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62
11. Nahrendorf, M., Hu, K., Hiller, K. H. et al. (2002) Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J. Am. Coll. Cardiol. 40, 1695-1700
12. Hayashidani, S., Tsutsui, H., Shiomi, T. et al. (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873
13. Nagaya, N., Nishikimi, T., Goto, Y. et al. (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am. Heart J. 135, 21-28
14. Yasuda, S., Goto, Y., Baba, T. et al. (2000) Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J. Am. Coll. Cardiol. 36, 115-121
15. Nakamura, H., Arakawa, K.., Itakura, H. et al. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised control trial. Lancet 368, 1155-1163
16. Fujimoto, N. and Iwata, K. (2001) Use of EIA to measure MMPs and TIMPs. Methods Mol. Biol. 151, 347-358
17. Yasuda, S., Goto, Y., Sumida, H. et al. (1999) Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 33, 1374-1378
18. Squire, I. B., Evans, J., Ng, L. L., Loftus, I. M. and Thompson, M. M. (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J. Card. Failure 10, 328-333
19. Matsunaga, T., Abe, N., Kameda, K. et al. (2005) Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int. J. Cardiol. 105, 203-208
20. Nakaya, R., Uzui, H., Shimizu, H. et al. (2005) Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int. J. Cardiol. 105, 67-73
21. Wagner, D. R., Delagardelle, C., Ernens, I., Rouy, D., Vaillant, M. and Beissel, J. (2006) Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J. Card. Failure 12, 66-72
22. Higo, S., Uematsu, M., Yamagishi, M. et al. (2005) Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ. J. 69, 1180-1185
23. Kai, H., Ikeda, H., Yasukawa, H. et al. (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32, 368-372
24. Fukuda, D., Shimada, K., Tanaka, A. et al. (2006) Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am. J. Cardiol. 97, 175-180
25. Kawakami, R., Saito, Y., Kishimoto, I. et al. (2004) Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110, 3306-3312
26. Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43
27. El Messal, M., Beaudeux, J. L., Drissi, A. et al. (2005) Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin. Chim. Acta 366, 185-189
28. Bader, M. (2002) Role of the local renin-angiotensin system in cardiac damage: a minireview focusing on transgenic animal models. J. Mol. Cell. Cardiol. 34, 1455-1462
29. Dechend, R., Fiebler, A., Lindschau, C. et al. (2001) Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am. J. Hypertens. 14, 55S-61S
30. Luo, J. D., Zhang, W. W., Zhang, G. P., Guan, J. X. and Chen, X. (1999) Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin. Exp. Pharmacol. Physiol. 26, 903-908